[1] Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 1998; 47, 1−57.
[2] Hayman DTS. Measles vaccination in an increasingly immunized and developed world. Hum Vaccin Immunother, 2019; 15, 28−33. doi:  10.1080/21645515.2018.1517074
[3] Dabbagh A, Patel MK, Dumolard L, et al. Progress Toward Regional Measles Elimination - Worldwide, 2000-2016. MMWR Morb Mortal Wkly Rep, 2017; 66, 1148−53. doi:  10.15585/mmwr.mm6642a6
[4] Ma C, Hao L, Zhang Y, et al. Monitoring progress towards the elimination of measles in China: an analysis of measles surveillance data. Bull World Health Organ, 2014; 92, 340−7. doi:  10.2471/BLT.13.130195
[5] Wang X, Boulton ML, Montgomery JP, et al. The epidemiology of measles in Tianjin, China, 2005-2014. Vaccine, 2015; 33, 6186−91. doi:  10.1016/j.vaccine.2015.10.008
[6] Wang Y, Liu R, Lu M, et al. Enhancement of safety and immunogenicity of the Chinese Hu191 measles virus vaccine by alteration of the S-adenosylmethionine (SAM) binding site in the large polymerase protein. Virology, 2018; 518, 210−20. doi:  10.1016/j.virol.2018.02.022
[7] Zheng J, Zhou Y, Wang H, et al. The role of the China Experts Advisory Committee on Immunization Program. Vaccine, 2010; 28, A84−7.
[8] Lixia W, Guang Z, Lee LA, et al. Progress in accelerated measles control in the People's Republic of China, 1991-2000. J Infect Dis, 2003; 187(Suppl 1), S252−7.
[9] Wagner AL, Zhang Y, Mukherjee B, et al. The impact of supplementary immunization activities on the epidemiology of measles in Tianjin, China. Int J Infect Dis, 2016; 45, 103−8.
[10] Paunio M, Hedman K, Davidkin I, et al. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. Expert Opin Pharmacother, 2003; 4, 1215−25. doi:  10.1517/14656566.4.8.1215
[11] Inouye S, Hasegawa A, Matsuno S, et al. Changes in antibody avidity after virus infections: detection by an immunosorbent assay in which a mild protein-denaturing agent is employed. J Clin Microbiol, 1984; 20, 525−9.
[12] Paunio M, Hedman K, Davidkin I, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect, 2000; 124, 263−71. doi:  10.1017/S0950268899003222
[13] de Souza VA, Pannuti CS, Sumita LM, et al. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J Med Virol, 1997; 52, 275−9. doi:  10.1002/(SICI)1096-9071(199707)52:3<275::AID-JMV7>3.0.CO;2-#
[14] Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis, 1998; 177, 1112−5. doi:  10.1086/517407
[15] Mercader S, Garcia P, Bellini WJ. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vaccine Immunol, 2012; 19, 1810−7. doi:  10.1128/CVI.00406-12
[16] National measles surveillance guideline. Beijing: Chinese Ministry of Health. http://www.moh.gov.cn/jkj/s3581/200902/9ea8e400444c45b0a48e3e55d929c9b5.shtml. [2018-10-13]. (In Chinese)
[17] Fu J, Jiang C, Wang J, et al. A hospital-associated measles outbreak in health workers in Beijing: implications for measles elimination in China, 2018. Int J Infect Dis, 2019; 78, 85−92. doi:  10.1016/j.ijid.2018.10.023
[18] Hagan JE, Kriss JL, Takashima Y, et al. Progress Toward Measles Elimination - Western Pacific Region, 2013-2017. MMWR Morb Mortal Wkly Rep, 2018; 67, 491−5. doi:  10.15585/mmwr.mm6717a3
[19] Ma C, Su QR, Wen N, et al. Measles epidemiology in China, 2014. Disease Surveillance, 2015; 30, 818−23.
[20] Boulton ML, Wang X, Zhang Y, et al. A population profile of measles susceptibility in Tianjin, China. Vaccine, 2016; 34, 3037−43. doi:  10.1016/j.vaccine.2016.04.094
[21] Hamkar R, Mahmoodi M, Nategh R, et al. Distinguishing between primary measles infection and vaccine failure reinfection by IgG avidity assay. East Mediterr Health J, 2006; 12, 775−82.
[22] Reyes MA, de Borrero MF, Roa J, et al. Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J, 1987; 6, 848−51. doi:  10.1097/00006454-198709000-00012
[23] Markowitz LE, Preblud SR, Fine PE, et al. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J, 1990; 9, 101−10. doi:  10.1097/00006454-199002000-00008
[24] Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis, 1990; 162, 1036−42. doi:  10.1093/infdis/162.5.1036
[25] Ma R, Lu L, Zhangzhu J, et al. A measles outbreak in a middle school with high vaccination coverage and evidence of prior immunity among cases, Beijing, China. Vaccine, 2016; 34, 1853−60. doi:  10.1016/j.vaccine.2015.11.006
[26] Mitchell P, Turner N, Jennings L, et al. Previous vaccination modifies both the clinical disease and immunological features in children with measles. J Prim Health Care, 2013; 5, 93−8. doi:  10.1071/HC13093
[27] Pannuti CS, Morello RJ, Moraes JC, et al. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. Clin Diagn Lab Immunol, 2004; 11, 119−22.
[28] Keeling MJ, Grenfell BT. Understanding the persistence of measles: reconciling theory, simulation and observation. Proc Biol Sci, 2002; 269, 335−43. doi:  10.1098/rspb.2001.1898
[29] Glass K, Grenfell BT. Waning immunity and subclinical measles infections in England. Vaccine, 2004; 22, 4110−6. doi:  10.1016/j.vaccine.2004.02.047
[30] Rosen JB, Rota JS, Hickman CJ, et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis, 2014; 58, 1205−10. doi:  10.1093/cid/ciu105
[31] Yaxing Ding, Yimin Sun, Yang Liu, et al. A measles outbreak in a middle school with high vaccination coverage in Tianjin,2016. Chinese Journal of Vaccines and Immunization. 2016; 23, 62-6. (In chinese)
[32] Sowers SB, Rota JS, Hickman CJ, et al. High Concentrations of Measles Neutralizing Antibodies and High-Avidity Measles IgG Accurately Identify Measles Reinfection Cases. Clin Vaccine Immunol, 2016; 23, 707−16. doi:  10.1128/CVI.00268-16
[33] Hickman CJ, Hyde TB, Sowers SB, et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J Infect Dis, 2011; 204(Suppl 1), S549−58.